HCPCS Level II · Drugs administered other than oral method
J9393Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J9393
J9393 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg.
It was added to HCPCS effective 01/01/2023, and its current record took effect 07/01/2024.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj, fulvestrant (teva)
- Date added
- 01/01/2023
- Action effective
- 07/01/2024
- BETOS
- O1E
Related J93xx codes
- J9301Injection, obinutuzumab, 10 mg
- J9302Injection, ofatumumab, 10 mg
- J9303Injection, panitumumab, 10 mg
- J9304Injection, pemetrexed (pemfexy), 10 mg
- J9305Injection, pemetrexed, not otherwise specified, 10 mg
- J9306Injection, pertuzumab, 1 mg
- J9307Injection, pralatrexate, 1 mg
- J9308Injection, ramucirumab, 5 mg
- J9309Injection, polatuzumab vedotin-piiq, 1 mg
- J9311Injection, rituximab 10 mg and hyaluronidase
- J9312Injection, rituximab, 10 mg
- J9313Injection, moxetumomab pasudotox-tdfk, 0.01 mg
Common questions about J9393
Is HCPCS J9393 still valid?
- Yes. J9393 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J9393?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.